Back to top

MTN-007 was a Phase I follow-up study to RMP-02/MTN-006 that found rectal use of a reduced glycerin formulation of tenofovir gel was safe and acceptable among the 60 men and women who took part in the study at three U.S. sites. Based on results, which were first reported in 2012, researchers proceeded with a Phase II trial of reduced glycerin tenofovir gel, MTN-017.  (See also MTN-006 and MTN-017.)

Gel Safe and Acceptable as Approach to Preventing HIV from Anal Sex in Early Phase Clinical Trial

3-April-2013

  

MTN-007 Backgrounder

14-March-2012  

  

MTN-007 Q&A

14-March-2012

  

See Also

MTN-007 Study Protocol

 

MTN-007 Study Page

 

Rectal Microbicides – Fact Sheet

21-Apr-2020

 

Reduced Glycerin Formulation of Tenofovir Vaginal Gel Safe for Rectal Use

17-May-2012

 

Rectal Formulation of Tenofovir Gel Found Safe and Acceptable in Early Phase Clinical Study

5-March-2012  

 

Researchers Reformulate Tenofovir Vaginal Gel for Rectal Use

28-February-2011

  

Promising HIV prevention microbicide tenofovir gel in new trial testing safety of rectal use

13-October-2010